LAUSR

Background: Pulmonary sarcomatoid carcinoma (PSC) is a recognized category of highly aggressive and poorly differentiated non-small-cell lung carcinoma (NSCLC), with five different subtypes: pleomorphic, spindle, giant cell, carcinosarcoma, and pulmonary blastoma. Although uncommon (0.1% to 0.4% of all pulmonary malignancies), their clinical importance is underscored by poorer prognosis and higher rate of resistance to conventional chemotherapy than other NSCLCs. And the incidence of MET 14 skipping in PSC is controversial. The aim of this study was to reveal the reliable frequency and the clinical-pathologic characteristics of PSC with MET 14 skipping in Chinese population. Method: A total of 35 patients with PSC were recruited between September 2007 and December 2017. The status of MET 14 skipping was detected by reverse transcription polymerase chain reaction (RTPCR). Results: Of this study, three patients were identified with MET 14 skipping in Chinese PSC population (2.86%, 1/35). The patient was a pulmonary pleomorphic carcinoma (PPC). Conclusion: The incidence rates of MET 14 skipping in PSC in the Chinese population are more than those of other subtypes of NSCLC. Crizotinib may serve as an effective treatment for MET 14 skipping PSC.